News
Resources
Blog
Sites
Nicole Longo Nicole is senior director of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.
Recent Posts
It’s a new year, but sadly Congress is still pursuing flawed price setting policies
By Nicole Longo | January 25, 2022
As we kick off 2022, Congress has a number of priorities they are aiming to tackle, including the Build Back Better Act (BBBA). Unfortunately, the bill includes policies that would take the...
Read More
A price control by any other name would still put patients at risk and threaten innovation
By Nicole Longo | December 9, 2021
Some policymakers in DC are laser focused on giving the government the power to “negotiate” in Medicare. What they aren’t saying is that this isn’t negotiation at all. They essentially just want...
Read More
Fact Check: Do contract pharmacies help patients access 340B medicines? No.
By Nicole Longo | November 2, 2021
Over the years, there has been repeated acknowledgement that the 340B program is often not supporting the patients it was intended to help. (If you need a reminder, check out this piece in the New...
Read More
New video: Why changes to the 340B program are essential for patients
By Nicole Longo | October 28, 2021
The 340B program is confusing. That’s a fact that likely no one would question. In fact, it is often forgotten in broader discussions about our health care system even though it is the second...
Read More
New analysis adds to research questioning whether 340B is working as Congress intended
By Nicole Longo | October 13, 2021
As the 340B program has grown over the past decade, there has been increased interest in it and ensuring it works in the best interest of patients. Unfortunately, study after study finds that...
Read More
Five reasons tying VA prices to Medicare Part D misses the mark
By Nicole Longo | September 22, 2021
Some members of Congress are considering a government “negotiation” plan that would tie medicine prices in Medicare to those in the U.S. Department of Veterans Affairs (VA). This misguided...
Read More
340B hospitals among those that provide lowest levels of community benefit across the country
By Nicole Longo | July 27, 2021
The 340B program reached $38 billion in sales at the discounted price in 2020. This is a 27% increase over sales in 2019, and the program is now more than four times the size it was in 2014....
Read More
Cross-country comparisons of medicine prices are like comparing apples to oranges
By Nicole Longo | March 22, 2021
Looking at differences in medicine prices between the United States and other countries can be misleading, often ignoring the complexities in the U.S. system and the repercussions of other...
Read More
Getting the 340B program back on track in 2021
By Nicole Longo | March 10, 2021
As our nation continues to fight a global pandemic, the need for access to affordable and quality health care feels even more pressing. This is especially true for vulnerable patients who have...
Read More
American biopharmaceutical manufacturing: Fueling economic growth now and for years to come
By Nicole Longo | December 21, 2020
As the world has grappled with the current pandemic, there has been increased focus on biopharmaceutical manufacturing and its global supply chain. Many wondered whether the biopharmaceutical...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
